{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32779326",
  "DateCompleted": {
    "Year": "2020",
    "Month": "12",
    "Day": "14"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "03",
    "Day": "28"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "08",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e2143",
      "10.1002/rmv.2143"
    ],
    "Journal": {
      "ISSN": "1099-1654",
      "JournalIssue": {
        "Volume": "30",
        "Issue": "6",
        "PubDate": {
          "Year": "2020",
          "Month": "Nov"
        }
      },
      "Title": "Reviews in medical virology",
      "ISOAbbreviation": "Rev Med Virol"
    },
    "ArticleTitle": "Drugs against SARS-CoV-2: What do we know about their mode of action?",
    "Pagination": {
      "StartPage": "1",
      "EndPage": "10",
      "MedlinePgn": "1-10"
    },
    "Abstract": {
      "AbstractText": [
        "The health emergency caused by the recent Covid-19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS-CoV-2). The first clinical trials have been testing repurposed drugs that show promising anti-SARS-CoV-2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid-19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS-CoV-2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in\u2009vitro and in\u2009vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid-19 stage. This review describes different candidate antiviral strategies for Covid-19, by focusing on their mechanism of action."
      ],
      "CopyrightInformation": "\u00a9 2020 John Wiley & Sons, Ltd."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-3497-5378"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire AFMB, Aix Marseille Universit\u00e9, CNRS, UMR 7257, Marseille, France."
          }
        ],
        "LastName": "Valle",
        "ForeName": "Coralie",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Beyond Humanity, Lyon, France."
          }
        ],
        "LastName": "Martin",
        "ForeName": "Baptiste",
        "Initials": "B"
      },
      {
        "Identifier": [
          "0000-0002-4734-2249"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unit\u00e9 des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), Marseille, France."
          }
        ],
        "LastName": "Touret",
        "ForeName": "Franck",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire AFMB, Aix Marseille Universit\u00e9, CNRS, UMR 7257, Marseille, France."
          }
        ],
        "LastName": "Shannon",
        "ForeName": "Ashleigh",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire AFMB, Aix Marseille Universit\u00e9, CNRS, UMR 7257, Marseille, France."
          }
        ],
        "LastName": "Canard",
        "ForeName": "Bruno",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire AFMB, Aix Marseille Universit\u00e9, CNRS, UMR 7257, Marseille, France."
          }
        ],
        "LastName": "Guillemot",
        "ForeName": "Jean-Claude",
        "Initials": "JC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unit\u00e9 des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), Marseille, France."
          }
        ],
        "LastName": "Coutard",
        "ForeName": "Bruno",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire AFMB, Aix Marseille Universit\u00e9, CNRS, UMR 7257, Marseille, France."
          }
        ],
        "LastName": "Decroly",
        "ForeName": "Etienne",
        "Initials": "E"
      }
    ],
    "GrantList": [
      {
        "GrantID": "101003627",
        "Agency": "European Union's Horizon 2020 research and innovation programme",
        "Country": "International"
      },
      {
        "GrantID": "101003627",
        "Agency": "SCORE project H2020 SC1-PHE-Coronavirus194 2020",
        "Country": "International"
      },
      {
        "Agency": "Fondation pour la Recherche M\u00e9dicale",
        "Country": "International"
      },
      {
        "Agency": "Inserm",
        "Country": "International"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Rev Med Virol",
    "NlmUniqueID": "9112448",
    "ISSNLinking": "1052-9276"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Combined Modality Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Management"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Susceptibility"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Development"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Repositioning"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors have no competing interest."
}